

# International Agency for Research on Cancer

---



**Governing Council  
Sixty-first Session**

*Lyon, 16–17 May 2019  
Auditorium*

Proposed Programme and Budget 2020–2021  
Budget and Information Tables (Revision 1)

The Budget and Information Tables contained in this document replace pages 21–30 and 33–39 of Document GC/61/6 Proposed Programme and Budget 2020–2021.

For clarity, the previous Budget Summary Tables I.1 and I.2 were replaced by Budget Summary Table I that provides the details of assessments on 25 Participating States for financing the Regular Budget 2020–2021.

In addition, Information Table F – Comparison of assessments on 25 and 26 Participating States was removed as the information contained therein is no longer relevant.

<b>Summary Table A</b> <b>PROPOSED REGULAR BUDGET FOR THE BIENNIUM 2020-2021</b> (expressed in euros)		
LEVEL 2 OBJECTIVES	2020-2021 BUDGET	%
1. Describe the occurrence of cancer	3,633,223	8.23
2. Understand the causes of cancer	11,972,571	27.12
3. Evaluate and implement cancer prevention and control strategies	4,153,150	9.41
4. Increase the capacity for cancer research	10,103,795	22.88
5. Provide strategic leadership and enhance the impact of the Agency's contribution to global cancer research	5,006,803	11.34
6. Enable and support the efficient conduct and coordination of research	9,280,251	21.02
<b>TOTAL BUDGET</b>	<b>44,149,793</b>	<b>100.00</b>

Summary Table B SUMMARY OF BIENNIAL RESOURCES BY LEVEL 2/3 OBJECTIVES AND SOURCES OF FUND (expressed in euros)							
Level 2 Level 3	Level 2 Objectives Level 3 Objectives	Regular Budget				Extra-Budgetary Resources (see note i)	
		2018-2019 Budget Amount	%	2020-2021 Budget Amount	%	2018-2019 Budget Amount	2020-2021 Budget Amount
<b>1</b>	<b>Describe the occurrence of cancer</b>						
1.1	Improve and expand reporting of descriptive cancer statistics	2,071,815		2,131,555		133,103	41,368
1.2	Support improved coverage and quality of cancer registration, particularly in low and middle-income countries (LMIC)	867,061		878,554		234,706	145,591
1.3	Improve tumour classification to inform cancer registration, research and treatment	568,517		623,114		1,180,345	2,134,225
		3,507,393	7.94	3,633,223	8.23	1,548,154	2,321,184
<b>2</b>	<b>Understand the causes of cancer</b>						
2.1	Identify the risk factors for human cancer through the conduct of epidemiological studies	7,054,967		7,011,378		3,729,425	3,939,992
2.2	Elucidate mechanisms of carcinogenesis through the conduct of laboratory studies	2,825,402		3,296,795		623,636	608,580
2.3	Provide expert evaluations of the available evidence-base to identify human carcinogens	1,838,737		1,664,398		1,581,599	473,071
		11,719,106	26.54	11,972,571	27.12	5,934,660	5,021,643
<b>3</b>	<b>Evaluate and implement cancer prevention and control strategies</b>						
3.1	Enhance understanding of interventions for cancer prevention and control	2,581,331		2,193,036		1,000,261	1,221,823
3.2	Enhance the implementation of cancer prevention and control programmes	1,200,232		1,521,118		2,679,898	1,731,170
3.3	Provide expert evaluations of the available evidence-base in order to recommend prevention strategies	536,225		438,996		143,650	36,188
		4,317,788	9.78	4,153,150	9.41	3,823,809	2,989,181
<b>4</b>	<b>Increase the capacity for cancer research</b>						
4.1	Increase human resources for cancer research	1,417,571		1,426,744		684,401	270,880
4.2	Develop new methodologies for cancer research	3,592,947		3,142,951		344,740	160,360
4.3	Provide the resources and infrastructure to support and enhance research	5,940,019		5,534,100		356,400	1,041,859
		10,950,537	24.80	10,103,795	22.88	1,385,541	1,473,099
<b>5</b>	<b>Provide strategic leadership and enhance the impact of the Agency's contribution to global cancer research</b>						
5.1	Define the vision and implement the scientific strategy of the Agency, providing the framework for the fulfilment of its objectives	1,358,283		1,335,215		0	0
5.2	Oversee the strategic direction of the Agency and the implementation of its programme	398,701		503,517		0	0
5.3	Create and maintain key strategic partnerships with national, regional and international organizations	617,675		630,214		0	0
5.4	Effectively communicate and disseminate the work of the Agency	2,425,289		2,537,857		998,669	874,935
		4,799,948	10.87	5,006,803	11.34	998,669	874,935
<b>6</b>	<b>Enable and support the efficient conduct and coordination of research</b>						
6.1	Ensure the Agency is directed and managed according to highest sector standards	8,396,098		8,760,406		2,663,912	4,142,370
6.2	Invest strategically towards increasing IARC's capacity	458,923		519,845		148,376	48,500
		8,855,021	20.06	9,280,251	21.02	2,812,288	4,190,870
	<b>TOTAL</b>	44,149,793	100.00	44,149,793	100.00	16,503,121	16,870,912

Notes:

i. Extra-budgetary resources include Voluntary Contributions secured at the time of budget submission, funding from the Programme Support Cost Account and the Governing Council Special Fund.

Summary Table C										
SUMMARY OF REGULAR BUDGET BY LEVEL 2/3 OBJECTIVES AND YEAR										
(expressed in euros)										
Level 2	Level 2 Objectives	2020			2021			2020-2021		
Level 3	Level 3 Objectives	Staff Budget	Non-Staff Budget	Total	Staff Budget	Non-Staff Budget	Total	Staff Budget	Non-Staff Budget	Total
<b>1</b>	<b>Describe the occurrence of cancer</b>									
1.1	Improve and expand reporting of descriptive cancer statistics	954,350	98,500	1,052,850	980,205	98,500	1,078,705	1,934,555	197,000	2,131,555
1.2	Support improved coverage and quality of cancer registration, particularly in low and middle-income countries (LMIC)	342,724	91,500	434,224	352,830	91,500	444,330	695,554	183,000	878,554
1.3	Improve tumour classification to inform cancer registration, research and treatment	253,619	55,000	308,619	259,495	55,000	314,495	513,114	110,000	623,114
		<b>1,550,693</b>	<b>245,000</b>	<b>1,795,693</b>	<b>1,592,530</b>	<b>245,000</b>	<b>1,837,530</b>	<b>3,143,223</b>	<b>490,000</b>	<b>3,633,223</b>
<b>2</b>	<b>Understand the causes of cancer</b>									
2.1	Identify the risk factors for human cancer through the conduct of epidemiological studies	3,003,398	470,683	3,474,081	3,082,614	454,683	3,537,297	6,086,012	925,366	7,011,378
2.2	Elucidate mechanisms of carcinogenesis through the conduct of laboratory studies	1,402,587	226,783	1,629,370	1,440,642	226,783	1,667,425	2,843,229	453,566	3,296,795
2.3	Provide expert evaluations of the available evidence-base to identify human carcinogens	663,627	160,000	823,627	680,771	160,000	840,771	1,344,398	320,000	1,664,398
		<b>5,069,612</b>	<b>857,466</b>	<b>5,927,078</b>	<b>5,204,027</b>	<b>841,466</b>	<b>6,045,493</b>	<b>10,273,639</b>	<b>1,698,932</b>	<b>11,972,571</b>
<b>3</b>	<b>Evaluate and implement cancer prevention and control strategies</b>									
3.1	Enhance understanding of interventions for cancer prevention and control	966,051	121,000	1,087,051	990,985	115,000	1,105,985	1,957,036	236,000	2,193,036
3.2	Enhance the implementation of cancer prevention and control programmes	621,862	130,000	751,862	637,256	132,000	769,256	1,259,118	262,000	1,521,118
3.3	Provide expert evaluations of the available evidence-base in order to recommend prevention strategies	157,639	60,000	217,639	161,357	60,000	221,357	318,996	120,000	438,996
		<b>1,745,552</b>	<b>311,000</b>	<b>2,056,552</b>	<b>1,789,598</b>	<b>307,000</b>	<b>2,096,598</b>	<b>3,535,150</b>	<b>618,000</b>	<b>4,153,150</b>
<b>4</b>	<b>Increase the capacity for cancer research</b>									
4.1	Increase human resources for cancer research	367,475	355,000	722,475	379,269	325,000	704,269	746,744	680,000	1,426,744
4.2	Develop new methodologies for cancer research	1,374,694	178,284	1,552,978	1,411,689	178,284	1,589,973	2,786,383	356,568	3,142,951
4.3	Provide the resources and infrastructure to support and enhance research	1,331,843	1,407,110	2,738,953	1,372,945	1,422,202	2,795,147	2,704,788	2,829,312	5,534,100
		<b>3,074,012</b>	<b>1,940,394</b>	<b>5,014,406</b>	<b>3,163,903</b>	<b>1,925,486</b>	<b>5,089,389</b>	<b>6,237,915</b>	<b>3,865,880</b>	<b>10,103,795</b>
<b>5</b>	<b>Provide strategic leadership and enhance the impact of the Agency's contribution to global cancer research</b>									
5.1	Define the vision and implement the scientific strategy of the Agency, providing the framework for the fulfilment of its objectives	404,183	260,000	664,183	411,032	260,000	671,032	815,215	520,000	1,335,215
5.2	Oversee the strategic direction of the Agency and the implementation of its programme	90,060	160,000	250,060	93,457	160,000	253,457	183,517	320,000	503,517
5.3	Create and maintain key strategic partnerships with national, regional and international organizations	237,282	75,000	312,282	237,932	80,000	317,932	475,214	155,000	630,214
5.4	Effectively communicate and disseminate the work of the Agency	985,966	276,060	1,262,026	1,009,891	265,940	1,275,831	1,995,857	542,000	2,537,857
		<b>1,717,491</b>	<b>771,060</b>	<b>2,488,551</b>	<b>1,752,312</b>	<b>765,940</b>	<b>2,518,252</b>	<b>3,469,803</b>	<b>1,537,000</b>	<b>5,006,803</b>
<b>6</b>	<b>Enable and support the efficient conduct and coordination of research</b>									
6.1	Ensure the Agency is directed and managed according to highest sector standards	3,435,134	890,690	4,325,824	3,536,084	898,498	4,434,582	6,971,218	1,789,188	8,760,406
6.2	Invest strategically towards increasing IARC's capacity	180,147	77,500	257,647	184,698	77,500	262,198	364,845	155,000	519,845
		<b>3,615,281</b>	<b>968,190</b>	<b>4,583,471</b>	<b>3,720,782</b>	<b>975,998</b>	<b>4,696,780</b>	<b>7,336,063</b>	<b>1,944,188</b>	<b>9,280,251</b>
<b>TOTAL</b>		<b>16,772,641</b>	<b>5,093,110</b>	<b>21,865,751</b>	<b>17,223,152</b>	<b>5,060,890</b>	<b>22,284,042</b>	<b>33,995,793</b>	<b>10,154,000</b>	<b>44,149,793</b>

Summary Table D SUMMARY OF REGULAR BUDGET FUNDED STAFF BY LEVEL 2/3 OBJECTIVES AND STAFF CATEGORY (expressed in person years)													
Level 2 Level 3	Level 2 Objectives Level 3 Objectives	2018 Staff Activity (person years)			2019 Staff Activity (person years)			2020 Staff Activity (person years)			2021 Staff Activity (person years)		
		Professional and above	General Service	Total Staff	Professional and above	General Service	Total Staff	Professional and above	General Service	Total Staff	Professional and above	General Service	Total Staff
<b>1</b>	<b>Describe the occurrence of cancer</b>												
1.1	Improve and expand reporting of descriptive cancer statistics	3.90	4.70	8.60	3.90	4.70	8.60	3.90	4.70	8.60	3.90	4.70	8.60
1.2	Support improved coverage and quality of cancer registration, particularly in low and middle-income countries (LMIC)	1.10	2.30	3.40	1.10	2.30	3.40	1.10	2.30	3.40	1.10	2.30	3.40
1.3	Improve tumour classification to inform cancer registration, research and treatment	1.00	0.60	1.60	1.00	0.60	1.60	0.95	0.95	1.90	0.95	0.95	1.90
		6.00	7.60	13.60	6.00	7.60	13.60	5.95	7.95	13.90	5.95	7.95	13.90
<b>2</b>	<b>Understand the causes of cancer</b>												
2.1	Identify the risk factors for human cancer through the conduct of epidemiological studies	14.00	13.65	27.65	14.30	13.65	27.95	13.87	12.50	26.37	13.87	12.50	26.37
2.2	Elucidate mechanisms of carcinogenesis through the conduct of laboratory studies	5.30	6.40	11.70	5.30	6.40	11.70	6.65	6.70	13.35	6.65	6.70	13.35
2.3	Provide expert evaluations of the available evidence-base to identify human carcinogens	3.80	2.50	6.30	3.80	2.50	6.30	3.00	2.75	5.75	3.00	2.75	5.75
		23.10	22.55	45.65	23.40	22.55	45.95	23.52	21.95	45.47	23.52	21.95	45.47
<b>3</b>	<b>Evaluate and implement cancer prevention and control strategies</b>												
3.1	Enhance understanding of interventions for cancer prevention and control	6.05	2.60	8.65	5.55	2.60	8.15	4.73	3.45	8.18	4.73	3.45	8.18
3.2	Enhance the implementation of cancer prevention and control programmes	3.35	0.95	4.30	3.35	0.95	4.30	3.85	1.50	5.35	3.85	1.50	5.35
3.3	Provide expert evaluations of the available evidence-base in order to recommend prevention strategies	1.20	0.90	2.10	1.20	0.90	2.10	1.00	0.25	1.25	1.00	0.25	1.25
		10.60	4.45	15.05	10.10	4.45	14.55	9.58	5.20	14.78	9.58	5.20	14.78
<b>4</b>	<b>Increase the capacity for cancer research</b>												
4.1	Increase human resources for cancer research	1.00	3.00	4.00	1.00	3.00	4.00	1.00	3.00	4.00	1.00	3.00	4.00
4.2	Develop new methodologies for cancer research	7.35	6.40	13.75	7.55	6.40	13.95	6.30	6.00	12.30	6.30	6.00	12.30
4.3	Provide the resources and infrastructure to support and enhance research	4.90	12.10	17.00	4.90	12.10	17.00	3.60	11.00	14.60	3.60	11.00	14.60
		13.25	21.50	34.75	13.45	21.50	34.95	10.90	20.00	30.90	10.90	20.00	30.90
<b>5</b>	<b>Provide strategic leadership and enhance the impact of the Agency's contribution to global cancer research</b>												
5.1	Define the vision and implement the scientific strategy of the Agency, providing the framework for the fulfilment of its objectives	1.60	1.25	2.85	1.60	1.25	2.85	1.60	1.25	2.85	1.60	1.25	2.85
5.2	Oversee the strategic direction of the Agency and the implementation of its programme	0.00	1.00	1.00	0.00	1.00	1.00	0.00	1.00	1.00	0.00	1.00	1.00
5.3	Create and maintain key strategic partnerships with national, regional and international organizations	1.35	0.50	1.85	1.35	0.50	1.85	1.35	0.50	1.85	1.35	0.50	1.85
5.4	Effectively communicate and disseminate the work of the Agency	5.00	3.00	8.00	5.00	3.00	8.00	5.00	3.00	8.00	5.00	3.00	8.00
		7.95	5.75	13.70	7.95	5.75	13.70	7.95	5.75	13.70	7.95	5.75	13.70
<b>6</b>	<b>Enable and support the efficient conduct and coordination of research</b>												
6.1	Ensure the Agency is directed and managed according to highest sector standards	11.45	22.75	34.20	11.45	22.75	34.20	12.15	21.90	34.05	12.15	21.90	34.05
6.2	Invest strategically towards increasing IARC's capacity	0.65	0.60	1.25	0.65	0.60	1.25	0.95	0.45	1.40	0.95	0.45	1.40
		12.10	23.35	35.45	12.10	23.35	35.45	13.10	22.35	35.45	13.10	22.35	35.45
<b>TOTAL</b>		73.00	85.20	158.20	73.00	85.20	158.20	71.00	83.20	154.20	71.00	83.20	154.20

Summary Table E ANALYSIS OF STAFFING AND RESOURCES BY LEVEL 2/3 OBJECTIVES (Staff activity expressed in person years and budget expressed in euros)											
Level 2	Level 2 Objectives	2020 STAFF ACTIVITY		2021 STAFF ACTIVITY		REGULAR BUDGETARY RESOURCES			EXTRA-BUDGETARY RESOURCES		
Level 3	Level 3 Objectives	Professional and above	General Service	Professional and above	General Service	Staff Budget 2020-2021	Non-staff Budget 2020-2021	Total 2020-2021	Staff Budget 2020-2021	Non-staff Budget 2020-2021	Total 2020-2021
<b>1</b>	<b>Describe the occurrence of cancer</b>										
1.1	Improve and expand reporting of descriptive cancer statistics	3.90	4.70	3.90	4.70	1,934,555	197,000	2,131,555	41,368	-	41,368
1.2	Support improved coverage and quality of cancer registration, particularly in low and middle-income countries (LMIC)	1.10	2.30	1.10	2.30	695,554	183,000	878,554	125,591	20,000	145,591
1.3	Improve tumour classification to inform cancer registration, research and treatment	0.95	0.95	0.95	0.95	513,114	110,000	623,114	1,107,225	1,027,000	2,134,225
		5.95	7.95	5.95	7.95	3,143,223	490,000	3,633,223	1,274,184	1,047,000	2,321,184
<b>2</b>	<b>Understand the causes of cancer</b>										
2.1	Identify the risk factors for human cancer through the conduct of epidemiological studies	13.87	12.50	13.87	12.50	6,086,012	925,366	7,011,378	1,377,438	2,562,554	3,939,992
2.2	Elucidate mechanisms of carcinogenesis through the conduct of laboratory studies	6.65	6.70	6.65	6.70	2,843,229	453,566	3,296,795	65,792	542,788	608,580
2.3	Provide expert evaluations of the available evidence-base to identify human carcinogens	3.00	2.75	3.00	2.75	1,344,398	320,000	1,664,398	327,955	145,116	473,071
		23.52	21.95	23.52	21.95	10,273,639	1,698,932	11,972,571	1,771,185	3,250,458	5,021,643
<b>3</b>	<b>Evaluate and implement cancer prevention and control strategies</b>										
3.1	Enhance understanding of interventions for cancer prevention and control	4.73	3.45	4.73	3.45	1,957,036	236,000	2,193,036	215,422	1,006,401	1,221,823
3.2	Enhance the implementation of cancer prevention and control programmes	3.85	1.50	3.85	1.50	1,259,118	262,000	1,521,118	576,170	1,155,000	1,731,170
3.3	Provide expert evaluations of the available evidence-base in order to recommend prevention strategies	1.00	0.25	1.00	0.25	318,996	120,000	438,996	36,188	-	36,188
		9.58	5.20	9.58	5.20	3,535,150	618,000	4,153,150	827,780	2,161,401	2,989,181
<b>4</b>	<b>Increase the capacity for cancer research</b>										
4.1	Increase human resources for cancer research	1.00	3.00	1.00	3.00	746,744	680,000	1,426,744	-	270,880	270,880
4.2	Develop new methodologies for cancer research	6.30	6.00	6.30	6.00	2,786,383	356,568	3,142,951	-	160,360	160,360
4.3	Provide the resources and infrastructure to support and enhance research	3.60	11.00	3.60	11.00	2,704,788	2,829,312	5,534,100	605,599	436,260	1,041,859
		10.90	20.00	10.90	20.00	6,237,915	3,865,880	10,103,795	605,599	867,500	1,473,099
<b>5</b>	<b>Provide strategic leadership and enhance the impact of the Agency's contribution to global cancer research</b>										
5.1	Define the vision and implement the scientific strategy of the Agency, providing the framework for the fulfilment of its objectives	1.60	1.25	1.60	1.25	815,215	520,000	1,335,215	-	-	-
5.2	Oversee the strategic direction of the Agency and the implementation of its programme	-	1.00	-	1.00	183,517	320,000	503,517	-	-	-
5.3	Create and maintain key strategic partnerships with national, regional and international organizations	1.35	0.50	1.35	0.50	475,214	155,000	630,214	-	-	-
5.4	Effectively communicate and disseminate the work of the Agency	5.00	3.00	5.00	3.00	1,995,857	542,000	2,537,857	774,935	100,000	874,935
		7.95	5.75	7.95	5.75	3,469,803	1,537,000	5,006,803	774,935	100,000	874,935
<b>6</b>	<b>Enable and support the efficient conduct and coordination of research</b>										
6.1	Ensure the Agency is directed and managed according to highest sector standards	12.15	21.90	12.15	21.90	6,971,218	1,789,188	8,760,406	1,494,401	2,647,969	4,142,370
6.2	Invest strategically towards increasing IARC's capacity	0.95	0.45	0.95	0.45	364,845	155,000	519,845	-	48,500	48,500
		13.10	22.35	13.10	22.35	7,336,063	1,944,188	9,280,251	1,494,401	2,696,469	4,190,870
<b>TOTAL</b>		71.00	83.20	71.00	83.20	33,995,793	10,154,000	44,149,793	6,748,084	10,122,828	16,870,912

<b>Summary Table F</b> <b>SUMMARY OF BUDGET CHANGES FROM PREVIOUS BIENNIAL BUDGET</b> (expressed in euros)		
Description	Amount (euros)	Percentage increase/decrease from 2018-2019
1. Budget for 2018-2019	44,149,793	
2. Real programme increase / (decrease)	(927,351)	-2.10%
3. Increase / (decrease) to unprogrammed reserve	0	0.00%
4. Cost increases / (decreases) due to statutory costs and inflation	927,351	2.10%
5. Budget for 2020-2021	44,149,793	0.00%

Summary Table G										
SUMMARY OF REGULAR BUDGET BY COMPONENT AND CAUSE OF INCREASE/DECREASE										
(expressed in euros)										
COMPONENT	2018-2019 Budget			2020-2021 Budget			BIENNIAL INCREASE/(DECREASE) 2020-2021 vs 2018-2019 <i>(see below note)</i>			
	2018	2019	2018-2019	2020	2021	2020-2021	Programme	Cost	Total	%
<b>Staff Budget:</b>										
Professional	10,687,269	10,922,991	21,610,260	10,473,603	10,685,515	21,159,118	(818,206)	367,064	(451,142)	-2.09%
General Service	6,159,249	6,423,774	12,583,023	6,299,038	6,537,637	12,836,675	(306,635)	560,287	253,652	2.02%
Total Staff Costs	16,846,518	17,346,765	34,193,283	16,772,641	17,223,152	33,995,793	(1,124,841)	927,351	(197,490)	-0.58%
<b>Non-Staff Budget:</b>										
Temporary assistance	40,000	59,000	99,000	40,000	43,200	83,200	(15,800)	0	(15,800)	-15.96%
Temporary advisors (experts, not coming for meetings)	99,300	99,300	198,600	102,000	107,000	209,000	10,400	0	10,400	5.24%
Other contractual arrangements (APWs, SSAs and consultants)	181,700	169,700	351,400	184,900	183,400	368,300	16,900	0	16,900	4.81%
Meetings (temporary advisors and participants)	253,000	315,000	568,000	348,500	412,500	761,000	193,000	0	193,000	33.98%
Duty travel (all categories of staff including fellows)	455,300	452,300	907,600	494,500	490,500	985,000	77,400	0	77,400	8.53%
Collaborative research agreements	323,400	248,400	571,800	236,500	218,500	455,000	(116,800)	0	(116,800)	-20.43%
Supplies	128,650	128,890	257,540	107,300	107,540	214,840	(42,700)	0	(42,700)	-16.58%
Equipment and furniture	167,960	147,990	315,950	170,380	134,500	304,880	(11,070)	0	(11,070)	-3.50%
Fellowships	715,900	553,900	1,269,800	656,800	564,800	1,221,600	(48,200)	0	(48,200)	-3.80%
Office services	144,300	144,970	289,270	133,250	133,120	266,370	(22,900)	0	(22,900)	-7.92%
Publications (including printing)	176,700	164,900	341,600	171,000	170,500	341,500	(100)	0	(100)	-0.03%
Library books & periodicals	143,000	153,500	296,500	140,230	148,490	288,720	(7,780)	0	(7,780)	-2.62%
Laboratory maintenance and supplies	297,450	297,450	594,900	356,250	356,250	712,500	117,600	0	117,600	19.77%
IT maintenance and licences	33,350	34,800	68,150	53,200	53,950	107,150	39,000	0	39,000	57.23%
Building services	1,570,000	1,593,000	3,163,000	1,627,300	1,665,640	3,292,940	129,940	0	129,940	4.11%
Staff Development & Training	88,000	79,800	167,800	83,000	83,000	166,000	(1,800)	0	(1,800)	-1.07%
Director's Development Provision	170,000	170,000	340,000	170,000	170,000	340,000	0	0	0	0.00%
Others	77,800	77,800	155,600	18,000	18,000	36,000	(119,600)	0	(119,600)	-76.86%
Total Non-Staff Costs	5,065,810	4,890,700	9,956,510	5,093,110	5,060,890	10,154,000	197,490	0	197,490	1.98%
Unprogrammed reserve	0	0	0	0	0	0	0	0	0	0.00%
<b>TOTAL REGULAR BUDGET</b>	21,912,328	22,237,465	44,149,793	21,865,751	22,284,042	44,149,793	(927,351)	927,351	0	0.00%
							-2.10%	2.10%	0.00%	

Note: Causes of budget changes are classified into two groups i.e. due to programmatic requirements ('Programme') and due to cost changes ('Cost').



Summary Table H								
SUMMARY OF REGULAR BUDGET AND PROPOSED FINANCING								
(expressed in euros)								
LEVEL 2 OBJECTIVES	2018	2019	2018-2019	%	2020	2021	2020-2021	%
1. Describe the occurrence of cancer	1,734,106	1,773,287	3,507,393	7.94%	1,795,693	1,837,530	3,633,223	8.23%
2. Understand the causes of cancer	5,768,989	5,950,117	11,719,106	26.54%	5,927,078	6,045,493	11,972,571	27.12%
3. Evaluate and implement cancer prevention and control strategies	2,196,452	2,121,336	4,317,788	9.78%	2,056,552	2,096,598	4,153,150	9.41%
4. Increase the capacity for cancer research	5,453,993	5,496,544	10,950,537	24.80%	5,014,406	5,089,389	10,103,795	22.88%
5. Provide strategic leadership and enhance the impact of the Agency's contribution to global cancer research	2,392,650	2,407,298	4,799,948	10.87%	2,488,551	2,518,252	5,006,803	11.34%
6. Enable and support the efficient conduct and coordination of research	4,366,138	4,488,883	8,855,021	20.06%	4,583,471	4,696,780	9,280,251	21.02%
Total Regular Budget	21,912,328	22,237,465	44,149,793	100.00%	21,865,751	22,284,042	44,149,793	100.00%
<b>PROPOSED FINANCING:</b> (see Summary Table I)								
Full financing from Participating States Assessments	21,912,328	22,237,465	44,149,793	100.00%	21,865,751	22,284,042	44,149,793	100.00%

Summary Table I											
SUMMARY OF PROPOSED FINANCING FROM ASSESSMENTS ON 25 PARTICIPATING STATES											
(expressed in euros)											
Participating States	Number of units assigned (see Note 1 & 2)	YEAR 2020			YEAR 2021			BIENNIUM 2020-2021	BIENNIUM 2018-2019	2020-2021 2018-2019	2020-2021 2018-2019
		70% of the assessed budget borne equally	30% of the assessed budget in accordance with the unit system	TOTAL	70% of the assessed budget borne equally	30% of the assessed budget in accordance with the unit system	TOTAL	TOTAL	TOTAL	% increase/ (decrease) (see Note 3)	Amount increase/ (decrease)
Australia	2	612,241	262,389	874,630	623,953	267,408	891,361	1,765,991	1,755,604	0.59	10,387
Austria	1	612,241	131,195	743,436	623,953	133,705	757,658	1,501,094	1,495,898	0.35	5,196
Belgium	1	612,241	131,195	743,436	623,953	133,705	757,658	1,501,094	1,495,898	0.35	5,196
Brazil	2	612,241	262,389	874,630	623,953	267,408	891,361	1,765,991	1,755,604	0.59	10,387
Canada	2	612,241	262,389	874,630	623,953	267,408	891,361	1,765,991	1,755,604	0.59	10,387
Denmark	1	612,241	131,195	743,436	623,953	133,705	757,658	1,501,094	1,495,898	0.35	5,196
Finland	0	612,241	0	612,241	623,953	0	623,953	1,236,194	1,236,194	0.00	0
France	4	612,241	524,777	1,137,018	623,953	534,817	1,158,770	2,295,788	2,275,015	0.91	20,773
Germany	4	612,241	524,777	1,137,018	623,953	534,817	1,158,770	2,295,788	2,275,015	0.91	20,773
India	1	612,241	131,195	743,436	623,953	133,705	757,658	1,501,094	1,495,898	0.35	5,196
Iran (Islamic Republic of)	0	612,241	0	612,241	623,953	0	623,953	1,236,194	0		1,236,194
Ireland	0	612,241	0	612,241	623,953	0	623,953	1,236,194	1,236,194	0.00	0
Italy	2	612,241	262,389	874,630	623,953	267,408	891,361	1,765,991	1,755,604	0.59	10,387
Japan	8	612,241	1,049,556	1,661,797	623,953	1,069,635	1,693,588	3,355,385	3,313,831	1.25	41,554
Morocco	0	612,241	0	612,241	623,953	0	623,953	1,236,194	1,236,194	0.00	0
Netherlands	1	612,241	131,195	743,436	623,953	133,705	757,658	1,501,094	1,495,898	0.35	5,196
Norway	1	612,241	131,195	743,436	623,953	133,705	757,658	1,501,094	1,495,898	0.35	5,196
Qatar	0	612,241	0	612,241	623,953	0	623,953	1,236,194	1,236,194	0.00	0
Republic of Korea	2	612,241	262,389	874,630	623,953	267,408	891,361	1,765,991	1,755,604	0.59	10,387
Russian Federation	2	612,241	262,389	874,630	623,953	267,408	891,361	1,765,991	1,755,604	0.59	10,387
Spain	2	612,241	262,389	874,630	623,953	267,408	891,361	1,765,991	1,755,604	0.59	10,387
Sweden	1	612,241	131,195	743,436	623,953	133,705	757,658	1,501,094	1,495,898	0.35	5,196
Switzerland	1	612,241	131,195	743,436	623,953	133,705	757,658	1,501,094	1,495,898	0.35	5,196
Turkey									1,495,898	-100.00	(1,495,898)
United Kingdom	4	612,241	524,777	1,137,018	623,953	534,817	1,158,770	2,295,788	2,275,015	0.91	20,773
United States of America	8	612,241	1,049,556	1,661,797	623,953	1,069,635	1,693,588	3,355,385	3,313,831	1.25	41,554
<b>TOTAL FUNDING</b>	<b>50</b>	<b>15,306,025</b>	<b>6,559,726</b>	<b>21,865,751</b>	<b>15,598,825</b>	<b>6,685,217</b>	<b>22,284,042</b>	<b>44,149,793</b>	<b>44,149,793</b>	<b>0.00</b>	<b>0</b>

Notes:

1. The method of assessment of contributions of Participating States is detailed in Resolutions GC/15/R9, GC/54/R18, and GC/56/R6.
2. Group classification of countries for the purpose of assigning units in accordance with the applicable GC resolutions is based on the WHO scale of assessments as adopted by the World Health Assembly in May 2017 (Resolution WHA70.9).
3. No increase in the overall assessment of contribution from Participating States.

Information Table A													
TOTAL STAFF AND NON-STAFF BUDGET BY SECTION AND GROUP													
(expressed in euros)													
Section	Group	2020				2021				2020-2021			
		Staff Budget	Non-staff Budget	Group Total Budget	Section Total Budget	Staff Budget	Non-staff Budget	Group Total Budget	Section Total Budget	Staff Budget	Non-staff Budget	Group Total Budget	Section Total Budget
<b>Scientific Programme (Objective 1-5)</b>													
CSU	CSU	1,297,074	190,000	1,487,074	<b>1,487,074</b>	1,333,035	190,000	1,523,035	<b>1,523,035</b>	2,630,109	380,000	3,010,109	<b>3,010,109</b>
DIR	DIR	657,937	505,000	1,162,937	<b>1,162,937</b>	665,591	510,000	1,175,591	<b>1,175,591</b>	1,323,528	1,015,000	2,338,528	<b>2,338,528</b>
DIR Others	COM	1,058,342	276,060	1,334,402	<b>2,837,194</b>	1,085,011	265,940	1,350,951	<b>2,853,046</b>	2,143,353	542,000	2,685,353	<b>5,690,240</b>
	ETR	367,475	355,000	722,475		379,269	325,000	704,269		746,744	680,000	1,426,744	
	LSB	560,317	220,000	780,317		577,826	220,000	797,826		1,138,143	440,000	1,578,143	
EDP	PRI	513,990	95,000	608,990	<b>1,158,198</b>	526,081	95,000	621,081	<b>1,181,622</b>	1,040,071	190,000	1,230,071	<b>2,339,820</b>
	SCR	454,208	95,000	549,208		465,541	95,000	560,541		919,749	190,000	1,109,749	
ENV	ENV	1,113,275	190,000	1,303,275	<b>1,303,275</b>	1,141,938	190,000	1,331,938	<b>1,331,938</b>	2,255,213	380,000	2,635,213	<b>2,635,213</b>
ESC	IHB	139,545	60,000	199,545	<b>1,368,233</b>	142,577	60,000	202,577	<b>1,395,281</b>	282,122	120,000	402,122	<b>2,763,514</b>
	IMO	609,345	160,000	769,345		624,431	160,000	784,431		1,233,776	320,000	1,553,776	
	WCT	339,343	60,000	399,343		348,273	60,000	408,273		687,616	120,000	807,616	
GEN	GCS	853,560	95,000	948,560	<b>1,741,899</b>	876,331	95,000	971,331	<b>1,782,724</b>	1,729,891	190,000	1,919,891	<b>3,524,623</b>
	GEP	698,339	95,000	793,339		716,393	95,000	811,393		1,414,732	190,000	1,604,732	
INF	ICB	511,610	95,000	606,610	<b>1,371,154</b>	525,639	95,000	620,639	<b>1,403,292</b>	1,037,249	190,000	1,227,249	<b>2,774,446</b>
	ICE	669,544	95,000	764,544		687,653	95,000	782,653		1,357,197	190,000	1,547,197	
MCA	EGE	708,804	95,000	803,804	<b>1,496,868</b>	728,793	95,000	823,793	<b>1,532,950</b>	1,437,597	190,000	1,627,597	<b>3,029,818</b>
	MMB	598,064	95,000	693,064		614,157	95,000	709,157		1,212,221	190,000	1,402,221	
NME	BMA	712,029	65,000	777,029	<b>1,851,918</b>	732,503	65,000	797,503	<b>1,876,091</b>	1,444,532	130,000	1,574,532	<b>3,728,009</b>
	NEP	406,512	85,000	491,512		415,730	65,000	480,730		822,242	150,000	972,242	
	NMB	518,377	65,000	583,377		532,858	65,000	597,858		1,051,235	130,000	1,181,235	
SSR	ASO/ITS	279,610	973,860	1,253,470	<b>1,253,470</b>	289,282	988,952	1,278,234	<b>1,278,234</b>	568,892	1,962,812	2,531,704	<b>2,531,704</b>
SSR	DAF (GCG/SCI)	90,060	160,000	250,060	<b>250,060</b>	93,457	160,000	253,457	<b>253,457</b>	183,517	320,000	503,517	<b>503,517</b>
<b>Administrative Programme (Objective 6)</b>													
SSR	ASO	1,014,987	773,190	1,788,177	<b>4,583,471</b>	1,050,870	788,998	1,839,868	<b>4,696,781</b>	2,065,857	1,562,188	3,628,045	<b>9,280,252</b>
	BFO	1,168,014	29,000	1,197,014		1,200,861	29,000	1,229,861		2,368,875	58,000	2,426,875	
	DAF	452,802	10,500	463,302		462,959	10,500	473,459		915,761	21,000	936,761	
	HRO	521,306	81,500	602,806		537,043	81,500	618,543		1,058,349	163,000	1,221,349	
	ITS	458,172	74,000	532,172		469,050	66,000	535,050		927,222	140,000	1,067,222	
TOTAL		16,772,641	5,093,110	21,865,751	21,865,751	17,223,152	5,060,890	22,284,042	22,284,042	33,995,793	10,154,000	44,149,793	44,149,793

<b>Information Table B</b>											
<b>UNITED NATIONS ACCOUNTING RATES OF EXCHANGE: EUROS TO US DOLLARS</b>											
From January 2008 to December 2018											
	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
January	0.686	0.730	0.693	0.761	0.774	0.754	0.725	0.850	0.922	0.956	0.837
February	0.676	0.762	0.714	0.734	0.763	0.737	0.737	0.882	0.882	0.937	0.805
March	0.661	0.782	0.741	0.728	0.746	0.773	0.731	0.943	0.895	0.937	0.815
April	0.634	0.759	0.743	0.710	0.753	0.783	0.727	0.923	0.887	0.942	0.810
May	0.642	0.744	0.774	0.675	0.755	0.764	0.723	0.904	0.882	0.921	0.828
June	0.643	0.717	0.819	0.702	0.805	0.767	0.735	0.894	0.897	0.893	0.848
July	0.636	0.711	0.811	0.699	0.804	0.767	0.736	0.905	0.901	0.879	0.864
August	0.658	0.712	0.763	0.700	0.816	0.754	0.748	0.915	0.895	0.847	0.875
September	0.698	0.695	0.787	0.688	0.797	0.755	0.759	0.889	0.897	0.832	0.858
October	0.729	0.688	0.735	0.733	0.777	0.737	0.787	0.891	0.906	0.848	0.865
November	0.773	0.676	0.720	0.707	0.772	0.726	0.803	0.912	0.920	0.861	0.880
December	0.758	0.664	0.764	0.750	0.770	0.736	0.820	0.914	0.942	0.844	0.879
Annual Average	0.683	0.720	0.755	0.716	0.778	0.754	0.753	0.902	0.902	0.891	0.847
Biennial Average		0.701		0.735		0.766		0.827		0.897	
		2008/2009		2010/2011		2012/2013		2014/2015		2016/2017	
Budget 2008/2009 approved at 0.815 €/US\$			Budget 2012/2013 approved at 0.675 €/US\$			Budget 2016/2017 approved at 0.729 €/US\$					
Budget 2010/2011 approved at 0.660 €/US\$			Budget 2014/2015 approved at 0.758 €/US\$			Budget 2018/2019 approved at 0.894 €/US\$					

Information Table C			
IARC PROJECT TREE STRUCTURE AND ASSOCIATED PROJECTS			
<b>LEVEL 1 OBJECTIVE: Reduce the burden of cancer worldwide through the conduct of research</b>			
<i>Level 2/3 Objectives</i>	<i>Level 4 Objectives</i>	<i>Project Number</i>	<i>Project Title</i>
<b>1 Describe the occurrence of cancer</b>			
1.1 Improve and expand reporting of descriptive cancer statistics	1.1.1 Expand the descriptive analyses of cancer incidence, mortality, prevalence and survival regionally and worldwide	PB.2021.CSU.03	Descriptive epidemiology of cancer
	1.1.2 Improve the validity, range, timeliness and dissemination of appropriate cancer indicators available at the national, regional and global level	PB.2021.CSU.01	Global cancer indicators: innovation and dissemination
1.2 Support improved coverage and quality of cancer registration, particularly in low and middle-income countries (LMIC)	1.2.1 Improve the availability, quality and dissemination of registry data, via IARC Regional Hubs and promote the role of population-based cancer registries in cancer control planning	PB.2021.CSU.02	Accelerating cancer registry support and development
1.3 Improve tumour classification to inform cancer registration, research and treatment	1.3.1 Publish WHO Classification of Tumours Series	PB.2021.WCT.01	WHO classification of tumours 5th series
<b>2 Understand the causes of cancer</b>			
2.1 Identify the risk factors for human cancer through the conduct of epidemiological studies	2.1.1 Advance understanding of the role of infectious agents	PB.2021.ICB.02	Determine the role of infectious agents in different human cancers
		PB.2021.ICE.02	Aetiology, natural history and burden of infection-associated cancers worldwide
	2.1.2 Advance understanding of the role of environmental, occupational and iatrogenic factors	PB.2021.ENV.01	To study carcinogenic effects of exposure to protracted low doses of ionising radiation
		PB.2021.ENV.02	To study exposure to non-ionising radiation (electromagnetic fields)
		PB.2021.ENV.03	To study cancers with suspected environmental, occupational or lifestyle-related causes
		PB.2021.ENV.04	To study unique environmental, lifestyle and occupational exposures
	2.1.3 Advance understanding of the role of dietary, metabolic and lifestyle factors	PB.2021.BMA.01	Metabolic and dietary biomarkers associated with cancer and intermediate end-points
		PB.2021.NEP.01	Molecular epidemiologic studies of nutrition and metabolism and cancer
		PB.2021.NMB.02	Dietary and lifestyle exposures associated with cancer and other non-communicable diseases
	2.1.4 Advance understanding of the role of genetic factors in influencing risk, and their interaction with non-genetic factors	PB.2021.GCS.01	Identify and understand genes involved in cancer development.
		PB.2021.GEP.01	Epidemiology of head and neck cancers
		PB.2021.GEP.02	Identifying causes of cancer through mutational signatures
		PB.2021.GEP.03	Mendelian randomization studies of multiple cancers
PB.2021.GEP.05		Kidney cancer molecular epidemiology	
2.2 Elucidate mechanisms of carcinogenesis through the conduct of laboratory studies	2.2.1 Advance understanding of biological and cellular pathways	PB.2021.EGE.01	Epigenetic alterations in studies of cancer causation and prevention
		PB.2021.ICB.01	Biological properties of infectious agents in in vitro and in vivo experimental models
		PB.2021.MMB.01	Toxicogenomics of environmental, lifestyle and occupational cancer risk factors
	2.2.2 Apply biomarkers to studies of cancer causes and molecular genetic classification of tumours	PB.2021.EGE.02	Epigenetics-based biomarkers in exposomics
		PB.2021.GCS.02	Multioomics (genomic, transcriptomic and epigenomic) molecular characterization of rare thoracic
		PB.2021.MMB.02	Molecular markers of exposure, cancer risk, tumor detection and classification
2.3 Provide expert evaluations of the available evidence-base to identify human carcinogens	2.3.1 Publish IARC Monographs and associated outputs on strategically related topics	PB.2021.IMO.01	IARC Monographs on the Evaluation of Carcinogenic Risks to Humans
<b>3 Evaluate and implement cancer prevention and control strategies</b>			
3.1 Enhance understanding of interventions for cancer prevention and control	3.1.1 Analyse the efficacy of primary cancer prevention strategies	PB.2021.GEP.04	Biomarkers of lung cancer risk
		PB.2021.ICE.01	Evaluation of HPV vaccination impact in low and middle-income countries
		PB.2021.PRI.03	Epidemiology and prevention of gastric cancer
	3.1.2 Analyse the efficacy of secondary cancer prevention strategies	PB.2021.PRI.02	Cervical cancer screening strategies for low- and middle-income countries
	3.1.3 Enhance understanding of the factors affecting cancer prognosis	PB.2021.ENV.05	To study lifestyle and environmental determinants of cancer risks, prognosis and cancer outcomes

Information Table C			
IARC PROJECT TREE STRUCTURE AND ASSOCIATED PROJECTS			
<b>LEVEL 1 OBJECTIVE: Reduce the burden of cancer worldwide through the conduct of research</b>			
Level 2/3 Objectives	Level 4 Objectives	Project Number	Project Title
3.2 Enhance the implementation of cancer prevention and control programmes	3.2.1 Identify factors influencing the effective implementation of primary and secondary prevention programmes	PB.2021.ENV.06	Expansion and evaluation of Cancer Prevention Recommendations
		PB.2021.PRI.01	Implementation studies of HPV and HBV vaccination
		PB.2021.SCR.01	Advancing cervical cancer elimination through improved access to screening, treatment & HPV
		PB.2021.SCR.02	Evaluation of colorectal cancer screening
		PB.2021.SCR.03	Improving the effectiveness of breast cancer screening, early diagnosis and treatment in LMICs
3.3 Provide expert evaluations of the available evidence-base in order to recommend prevention strategies	3.3.1 Publish IARC Handbooks on Cancer Prevention	PB.2021.SCR.04	Reporting the cancer screening initiatives & their impact in 5 Continents (CanScreen5)
		PB.2021.IHB.01	IARC Handbooks Programme
<b>4 Increase the capacity for cancer research</b>			
4.1 Increase human resources for cancer research	4.1.1 Award fellowships and provide training through participation in collaborative research projects	PB.2021.ETR.01	IARC Research Training and Fellowship Programme
		PB.2021.ETR.02	IARC Courses
4.2 Develop new methodologies for cancer research	4.2.1 Improve and implement epidemiological, statistical and bioinformatics methods	PB.2021.ENV.07	Contribute to advanced biostatistical analyses and developing biostatistical methods
		PB.2021.ICE.03	Social inequalities and socio-economic transitions in cancer
		PB.2021.NMB.01	Integration of lifestyle and molecular exposures in aetiological models for cancer research
	4.2.2 Improve and implement laboratory methods	PB.2021.BMA.02	Metabolomics-based development of biomarkers of foods, food constituents, food contaminants and metabolism
		PB.2021.EGE.03	Epigenomic profiling applicable to molecular epidemiology and carcinogen evaluation
		PB.2021.GCS.03	Non-invasive biomarkers for early detection of cancer.
		PB.2021.MMB.03	Experimental and bioinformatic methodologies for molecular epidemiology and laboratory cancer
		PB.2021.NEP.02	Molecular biomarkers for nutrition assessment in cancer epidemiology
4.3 Provide the resources and infrastructure to support and enhance research	4.3.1 Develop and maintain research platforms	PB.2021.LSB.01	Management of IARC biobank and pre-analytical processing services
		PB.2021.LSB.03	Capacity Building and Biobank Infrastructure support globally, including in Low and Middle Income
		PB.2021.GCS.04	Genetics Platform.
	4.3.2 Develop and maintain laboratory and computing services	PB.2021.LSB.02	Laboratory Services Support
		PB.2021.MMB.04	The IARC TP53 Database
		PB.2021.SSR.01	Laboratory and computing services
		PB.2021.WCT.02	Histopathology core facility
		PB.2021.DIR.03	Strategic Research Investment
4.3.3 Respond to emerging research opportunities and demands by supporting new or ongoing initiatives			
<b>5 Provide strategic leadership and enhance the impact of the Agency's contribution to global cancer research</b>			
5.1 Define the vision and implement the scientific strategy of the Agency, providing the framework for the fulfilment of its objectives	5.1.1 Define the vision and implement the scientific strategy of the Agency, providing the framework for the fulfilment of its objectives	PB.2021.DIR.01	Direction and leadership
5.2 Oversee the strategic direction of the Agency and the implementation of its programme	5.2.1 Oversee the strategic direction of the Agency and the implementation of its programme	PB.2021.SSR.02	Support to Governing and Scientific Council meetings and interactions with Participating States
5.3 Create and maintain key strategic partnerships with national, regional and international organizations	5.3.1 Create and maintain key strategic partnerships with national, regional and international organizations	PB.2021.DIR.02	Strategic Partnerships
5.4 Effectively communicate and disseminate the work of the Agency	5.4.1 Effectively communicate and disseminate the work of the Agency	PB.2021.COM.01	Information Services and Dissemination
		PB.2021.COM.02	Editing, Layout and Translation
		PB.2021.COM.03	Media Relations, Multimedia, and Web Services
<b>6 Enable and support the efficient conduct and coordination of research</b>			
6.1 Ensure the Agency is directed and managed according to highest sector standards	6.1.1 Provide sound management of human and infrastructure resources	PB.2021.SSR.03	Sound management of human and infrastructure resources
		PB.2021.SSR.04	Nouveau Centre
	6.1.2 Ensure the funding requirements for the Agency's activities are met and available resources are disbursed in line with the strategy	PB.2021.SSR.05	Management of Agency's financial resources and resource mobilization
6.2 Invest strategically towards increasing IARC's capacity	6.2.1 Ensure a work culture that encourages exploring new approaches and opportunities	PB.2021.SSR.06	Work culture to encourage new approaches and opportunities

Information Table D COMPARISON OF PROPOSED REGULAR BUDGET 2020-2021 WITH APPROVED REGULAR BUDGET 2018-2019 BY LEVEL 2/3 OBJECTIVES (expressed in euros)								
Level 2	Level 2 Objectives	REGULAR BUDGETARY RESOURCES			Increase/(Decrease) from 2018-2019			% Change
		Staff Budget 2020-2021	Non-staff Budget 2020-2021	Total 2020-2021	Staff Budget	Non-staff Budget	Total	
Level 3	Level 3 Objectives							
<b>1</b>	<b>Describe the occurrence of cancer</b>							
1.1	Improve and expand reporting of descriptive cancer statistics	1,934,555	197,000	2,131,555	42,740	17,000	59,740	2.88
1.2	Support improved coverage and quality of cancer registration, particularly in low and middle-income countries (LMIC)	695,554	183,000	878,554	18,493	-7,000	11,493	1.33
1.3	Improve tumour classification to inform cancer registration, research and treatment	513,114	110,000	623,114	50,597	4,000	54,597	9.60
		3,143,223	490,000	3,633,223	111,830	14,000	125,830	3.59
<b>2</b>	<b>Understand the causes of cancer</b>							
2.1	Identify the risk factors for human cancer through the conduct of epidemiological studies	6,086,012	925,366	7,011,378	-96,155	52,566	-43,589	-0.62
2.2	Elucidate mechanisms of carcinogenesis through the conduct of laboratory studies	2,843,229	453,566	3,296,795	437,227	34,166	471,393	16.68
2.3	Provide expert evaluations of the available evidence-base to identify human carcinogens	1,344,398	320,000	1,664,398	-254,339	80,000	-174,339	-9.48
		10,273,639	1,698,932	11,972,571	86,733	166,732	253,465	2.16
<b>3</b>	<b>Evaluate and implement cancer prevention and control strategies</b>							
3.1	Enhance understanding of interventions for cancer prevention and control	1,957,036	236,000	2,193,036	-169,295	-219,000	-388,295	-15.04
3.2	Enhance the implementation of cancer prevention and control programmes	1,259,118	262,000	1,521,118	181,886	139,000	320,886	26.74
3.3	Provide expert evaluations of the available evidence-base in order to recommend prevention strategies	318,996	120,000	438,996	-157,229	60,000	-97,229	-18.13
		3,535,150	618,000	4,153,150	-144,638	-20,000	-164,638	-3.81
<b>4</b>	<b>Increase the capacity for cancer research</b>							
4.1	Increase human resources for cancer research	746,744	680,000	1,426,744	22,173	-13,000	9,173	0.65
4.2	Develop new methodologies for cancer research	2,786,383	356,568	3,142,951	-408,364	-41,632	-449,996	-12.52
4.3	Provide the resources and infrastructure to support and enhance research	2,704,788	2,829,312	5,534,100	-412,637	6,718	-405,919	-6.83
		6,237,915	3,865,880	10,103,795	-798,828	-47,914	-846,742	-7.73
<b>5</b>	<b>Provide strategic leadership and enhance the impact of the Agency's contribution to global cancer research</b>							
5.1	Define the vision and implement the scientific strategy of the Agency, providing the framework for the fulfilment of its objectives	815,215	520,000	1,335,215	-3,068	-20,000	-23,068	-1.70
5.2	Oversee the strategic direction of the Agency and the implementation of its programme	183,517	320,000	503,517	3,816	101,000	104,816	26.29
5.3	Create and maintain key strategic partnerships with national, regional and international organizations	475,214	155,000	630,214	7,539	5,000	12,539	2.03
5.4	Effectively communicate and disseminate the work of the Agency	1,995,857	542,000	2,537,857	112,568	0	112,568	4.64
		3,469,803	1,537,000	5,006,803	120,855	86,000	206,855	4.31
<b>6</b>	<b>Enable and support the efficient conduct and coordination of research</b>							
6.1	Ensure the Agency is directed and managed according to highest sector standards	6,971,218	1,789,188	8,760,406	365,636	-1,328	364,308	4.34
6.2	Invest strategically towards increasing IARC's capacity	364,845	155,000	519,845	60,922	0	60,922	13.27
		7,336,063	1,944,188	9,280,251	426,558	-1,328	425,230	4.80
	<b>TOTAL</b>	33,995,793	10,154,000	44,149,793	-197,490	197,490	0	0.00

Information Table E												
GROUP CLASSIFICATION OF COUNTRIES AND ASSIGNING UNITS FOR ASSESSED CONTRIBUTIONS												
From 2014 to 2021												
GROUP CLASSIFICATION OF COUNTRIES AS PER RESOLUTION GC/15/R9												
WHO's % Contribution			IARC Group			IARC Scale (# units)						
8% and above			1			8						
4% and above; below 8%			2			4						
2% and above; below 4%			3			2						
0.5% and above; below 2%			4			1						
less than 0.5%			5			0						
GROUP AND UNIT ASSIGNED TO EACH PARTICIPATING STATE												
Participating State	SCALE for 2020-2021 PROPOSED BUDGET			SCALE for 2018-2019 APPROVED BUDGET			SCALE for 2016-2017 APPROVED BUDGET			SCALE for 2014-2015 APPROVED BUDGET		
	WHO's % Contribution (EB144.R6)	IARC Group	IARC Scale (# units)	WHO's % Contribution (WHA70.9)	IARC Group	IARC Scale (# units)	WHO's % Contribution (WHA68.12)	IARC Group	IARC Scale (# units)	WHO's % Contribution (WHA66.15)	IARC Group	IARC Scale (# units)
Australia	2.2101	3	2	2.3371	3	2	2.0741	3	2	2.0741	3	2
Austria	0.6770	4	1	0.7201	4	1	0.7981	4	1	0.7981	4	1
Belgium	0.8211	4	1	0.8851	4	1	0.9981	4	1	0.9981	4	1
Brazil	2.9482	3	2	3.8232	3	2	2.9342	3	2	2.9342	3	2
Canada	2.7342	3	2	2.9211	3	2	2.9842	3	2	2.9842	3	2
Denmark	0.5540	4	1	0.5840	4	1	0.6750	4	1	0.6750	4	1
Finland	0.4210	5	0	0.4560	5	0	0.5190	4	1	0.5190	4	1
France	4.4273	2	4	4.8592	2	4	5.5935	2	4	5.5935	2	4
Germany	6.0904	2	4	6.3892	2	4	7.1416	2	4	7.1416	2	4
India	0.8341	4	1	0.7370	4	1	0.6660	4	1	0.6660	4	1
Iran (Islamic Republic of)	0.3980	5	0	0.4710	5	0	0.3560	5	0	0.3560	5	0
Ireland	0.3710	5	0	0.3350	5	0	0.4180	5	0	0.4180	5	0
Italy	3.3072	3	2	3.7482	3	2	4.4483	2	4	4.4483	2	4
Japan	8.5645	1	8	9.6802	1	8	10.8338	1	8	10.8338	1	8
Morocco	0.0550	5	0	0.0540	5	0	0.0620	5	0	0.0620	5	0
Netherlands	1.3561	4	1	1.4821	4	1	1.6541	4	1	1.6541	4	1
Norway	0.7540	4	1	0.8491	4	1	0.8511	4	1	0.8511	4	1
Qatar	0.2820	5	0	0.2690	5	0	0.2090	5	0	0.2090	5	0
Republic of Korea	2.2671	3	2	2.0391	3	2	1.9941	4	1	1.9941	4	1
Russian Federation	2.4052	3	2	3.0882	3	2	2.4382	3	2	2.4382	3	2
Spain	2.1461	3	2	2.4431	3	2	2.9732	3	2	2.9732	3	2
Sweden	0.9061	4	1	0.9561	4	1	0.9601	4	1	0.9601	4	1
Switzerland	1.1511	4	1	1.1401	4	1	1.0471	4	1	1.0471	4	1
Turkey	1.3711	4	1	1.0181	4	1	1.3281	4	1	1.3281	4	1
United Kingdom of Great Britain and Northern Ireland	4.5673	2	4	4.4632	2	4	5.1794	2	4	5.1794	2	4
United States of America	22.0000	1	8	22.0000	1	8	22.0000	1	8	22.0000	1	8